Dr. Palmbos on the use of chemoimmunotherapy in patients with bladder cancer
Phillip Palmbos, MD, PhD, assistant professor, University of Michigan Health, discusses the current state of chemoimmunotherapy use in patients with bladder cancer. Palmbos explains that sequential use of chemotherapy and immunotherapy in patients with locally advanced or metastatic urothelial cancer has emerged as an option following positive overall survival (OS) data from the phase 3 JAVELIN Bladder 100 trial (NCT02603432), which assessed maintenance avelumab (Bavencio) following frontline chemotherapy in this patient population. However, Palmbos says that combined chemoimmunotherapy still cannot be recommended because findings from the phase 3 IMvigor130 (NCT02807636) and KEYNOTE-361 (NCT02853305) trials did not demonstrate an OS benefit with simultaneous chemoimmunotherapy in patients with bladder cancer. Ongoing research is attempting to clarify the role of the treatment approach in this setting.
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
